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Abstract
The natural history and inheritance of familial papillary thyroid carcinoma (FPTC) remain unclear. A specific 
genetic defect responsible for this condition and its inheritance is yet to be established. The penetrance, mode of 
inheritance and treatment of this familial thyroid condition are different from other familial thyroid conditions 
(familial medullary thyroid cancer). Presented here is a family of four sisters in which three developed multi-
focal PTC. A 47-year-old lady presented with incidental finding of multinodular goitre and normal thyroid 
function. She had three other sisters who were diagnosed with PTC at age 46, 48 and 49 years. Detailed clinical 
history of her sisters was gathered from them over telephone as they all moved to different parts of world in 
their twenties. Literature review was carried out to find similar patients reported in literature. Environmental 
factors were less important in the development of PTC in this family. It was also interesting that all three were 
diagnosed with the condition at a very similar age. FPTC behaviour was not more aggressive than sporadic 
form of disease. There is not enough evidence in literature to suggest prophylactic thyroidectomy in relatives 
of patients with PTC. Since the exact inheritance pattern of this condition is not known, detailed family history 
is important in patients with thyroid disorders to identify high-risk patients. Genetic factors are much more 
important than environmental factors in the development of this condition. The first-degree relatives should 
be assessed clinically for further investigations if two individuals in the same family develop the condition at 
similar age.
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Introduction
Thyroid cancer is the most common endocrine malignancy 
and demonstrated approximately two and a half-fold 
increase from 1973 to 2002.[1] This increase in incidence 
is sometimes put down to early detection of pathology due 
to improvement in health-care facilities as the mortality 
rates remain the same over the years.[2] Relative risk 
of familial primary cancer in thyroid gland is between 
5- and 10.4-fold. This turns out to be the highest relative 
risk of familial cancer compared with all other organs.[3] 
Papillary thyroid carcinoma (PTC) constitutes 80% of all 
thyroid cancers (1). About 5–15% of these PTC cases[4] 




A 47-year-old lady presented with multinodular goitre. She 
was incidentally found to have multinodular goitre by her 
general practitioner during clinic appointment for upper 
respiratory tract infection. She denied any change in her 
voice, swallowing or breathing difficulties and no clinical 
features of hypo- or hyper-thyroidism. She currently 
smoked 10–15 cigarettes per day, drank 5 to 10 units of 
alcohol in a week and not allergic to any medication. She 
always lived in London and worked as an accountant. She 
did not take regular medications and not suffered from any 
chronic illness. To the best of her knowledge, neither her 
parents nor any other relatives had any thyroid-related 
problems except her three elder sisters and all of them 
had PTC. All of them were diagnosed between the ages 
of 45 and 50 years. She had two daughters and a son and 
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none of them suffered from thyroid-related problems. 
On examination, she had multinodular goitre, no lymph 
nodes in neck and no signs of thyroid eye disease. She 
then had ultrasound (US) guided fine-needle aspirations 
(FNAs) of one nodule in each lobe of the thyroid gland, 
which were reported as Thy 2. The nodules were selected 
on US and all the nodules were reported low risk by US 
criteria. The FNA was repeated 7 months later and once 
again reported Thy 2. Following discussion in MDT, it 
was decided to continue monitoring her thyroid nodules 
with US and clinical examination.
Case 2
Her eldest sister presented to this hospital about 7 years 
ago with difficulty in swallowing with a long-standing 
multinodular goitre. She was 49 years old at that time. 
She did not notice change in size of her gland before 
presentation and her breathing and voice remained 
unaffected. Her barium swallow showed no obstruction 
at level of thyroid gland and flow volume loops were 
also normal. Her thyroid FNA of a right-sided 2.7 × 2.1 
× 2.2 mm nodule was reported Thy 5 and histopathology 
report of biopsy specimen confirmed multifocal PTC 
following thyroidectomy. She lived in London till the age 
of 19 years and then moved to New York. She worked 
in the financial market till age 47 years and returned to 
London 2 years ago. She denied radiation or chemical 
exposure all her life. No metastases were identified, biopsy 
reported multifocal papillary carcinoma of thyroid and she 
remains disease free till now. She had two daughters and 
one of them had multinodular goitre.
Case 3
Her other elder sister lived in Italy since the age of 24. 
She worked as a fashion designer and had Thy 5 on her 
FNA there in Italy at age 46. Her biopsy specimen also 
showed multifocal papillary carcinoma of thyroid gland. 
She also had no exposure to radiations or chemicals and 
remains disease free after thyroidectomy. Her biopsy 
reported multifocal papillary carcinoma of thyroid. Her 
wound was complicated by keloid scar. Plastic surgery 
improved it, but it did not improve to her satisfaction. She 
had a son and a daughter. Her son had multinodular goitre 
and was receiving carbimazole for overactive thyroid 
gland. No more information about his medical condition 
could be sought.
Case 4
Her third sister also had very similar presentation and 
diagnosed at age 48 years. She had FNA about 10 years 
ago in Spain and further follow-up was not considered 
necessary in view of stable multinodular goitre and benign 
FNA. She worked as journalist and travelled a lot during 
her job. Her biopsy following total thyroidectomy reported 
0.8 mm unifocal papillary carcinoma and no evidence of 
metastasis were detected. She remains disease free to date. 
She had no children.
Discussion
This family shows most of the features of FPTC reported 
in literature. Most of the patients suffering from FPTC are 
younger in age than non-FPTC patients and severity of 
FPTC increases in successive generations. Not only that 
FPTC patients frequently present with more aggressive 
tumours but also there is also a higher incidence of 
multifocal tumour deposits among such patients. Invasion 
of surrounding tissues including metastasis to lymph 
nodes is also more frequently found among patients of 
FPTC compared to non-FPTC patients.[4] Like most other 
thyroid-related conditions, women make most of the 
patients of sporadic PTC. Men and children are usually 
less likely to be affected by FPTC.[5] One should consider 
FPTC a possible diagnosis in a family when men and 
children outnumber women with PTC. In medical history 
of patients who present with thyroid nodules, one should 
always try to find out exact nature of condition if a male 
member of family suffered from thyroid disorder. All 
these features suggest a worse form of papillary cancer 
compared to sporadic form of this disease. There have 
been no clinical trials so far to suggest that these features 
could be used as criteria for screening other family 
members, but clinicians should keep a low threshold for 
investigating symptomatic family members of patients 
who present with above features.
Small sample size of patients with FPTC poses a challenge 
to devise a reliable screening or diagnostic criteria for this 
condition. One of the studies diagnosed FPTC when three 
or more family members had PTC. FPTC is very much 
a diagnosis of exclusion so none of these patients should 
be suffering from any of the other known syndromes or 
conditions associated with thyroid cancers.[4,5] Genetic 
and environmental factors are believed to be the two most 
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common and important factors in causation and inheritance 
of most of the cancers. In most of the patients, it is difficult 
to identify the factors responsible for this condition and its 
inheritance as they all share same genetic background and 
environmental factors. Not only that most cases of FPTC 
have a small pedigree but they also present with a variety 
of thyroid-related additional conditions. Most of these 
conditions are benign, but some may be contributing to 
the development of thyroid cancer. The presence of these 
additional conditions has made identification of genetic 
factors and the molecular alterations at the origin of the 
pathology very challenging.[5,6]
One should expect a certain set of specific genes inherited 
from one generation to another in these patients of FPTC. The 
inheritance pattern of this condition is still not clear. Genetic 
studies on patients with non-FPTC have managed to identify 
certain gene sequences associated with this condition. The 
point mutations of BRAF genes and rearrangements of 
chromosomes of the RET/PTC have been found in patients 
of sporadic PTC. Serine/threonine-protein kinases, a product 
of BRAF gene is involved in regulating MAP kinase/ERKs 
second messenger pathways. These signalling pathways 
influence functioning of cells including cell differentiation, 
cell division and secretion. Point mutations in BRAF are 
found in just under half (45%) PTC cases.[7] The involvement 
of this particular gene in a significant number of PTC 
patients has generated a lot of interest in this gene. Although 
BRAF is associated with a significant number of patients 
with non-FPTC, it is not associated with a sizeable number 
of patients with FPTC. This raises the question that is there 
separate genes responsible for non-FPTC and FPTC? This 
remains unanswered until we find the definitive genes 
responsible for each condition.
The other most commonly associated gene with non-
FPTC was RET. Rearrangements of the RET are 
found in about 35% of sporadic PTC. The RET proto-
oncogene is one of the receptor tyrosine kinases. These 
tyrosine kinase receptors are located on cell surface and 
transduce signals inside cell which affects cell growth and 
differentiation.[7] This rearrangement of RET affects cell 
growth and differentiation. It has been associated with 
some other forms of cancers as well. Such a high incidence 
of these genetic mutations in BRAF and RET strongly 
suggests their association with non-FPTC; however, 
there should be effect of these mutations on germ line 
for these to be inheritable. In a study, germ line mutations 
of single-nucleotide polymorphisms in these genes were 
also reported to act as modifiers in the cancer process.[8]
Not as many genes are linked with FPTC as many 
with sporadic PTC. Some of the regions have been 
identified which can potentially harbour an FPTC 
gene: Chromosomal region 1q21 linked to FPTC with 
papillary renal neoplasia,[9] 2q21 linked to familial NMTC 
type 1 syndrome[10] and the telomere abnormalities and 
chromosome fragility might display in FPTC family;[11] 
specifically, familial NMTC and its relationship with 
familial MNG are recognized as distinct clinical entities, 
and the molecular pathophysiology of MNG and PTC is 
different, indeed, MNG1 is located at 14q;[12] however, 
one study in a kindred with MNG and PTC suggested 
that 14q32 linked to a form of inherited MNG syndrome 
with a significant risk of progression to PTC.[13] These 
findings are suggestive of a possible relationship between 
these genetic mutations and FPTC, but none of these 
are conclusive. Like any other familial conditions, the 
specific set of genetic mutations should be transmitted 
from one generation to the next to confirm familial nature 
of the condition. Liao et al. in their study concluded 
that in Chinese familial multinodular goitre (fMNG) 
with PTC, the risk allele homozygote of rs966423 
(CC) at 2q35, rs2910164 (CC) at 5q24 and rs2439302 
(GG) at 8p12 could contribute to the fMNG with PTC, 
while the other identified risk alleles for sporadic 
PTC or radiation-related PTC might not be involved. 
Furthermore, corresponding to the previous studies on 
the association between chromosome 14q and fMNG 
with PTC, their work approved that rs944289 but not 
rs116909374 at 14q13 locus might be associated with 
genetic predisposition to a Chinese family MNG with 
PTC. Although several different heterozygous alleles in 
the RET introns presented, the common BRAF and RET 
mutations were not susceptibility genetic events in this 
Chinese family.[14] Clinicians have to be very careful about 
bringing up the word ‘familial’ with patients during their 
treatment. The most obvious subsequent question would 
be the risk of that condition in their children or siblings. 
Due to lack of evidence about genes linked to FPTC, 
the risk in subsequent generations cannot be quantified 
and no specific gene studies are routinely performed to 
look for any specific genes in high-risk patients so far. 
In this scenario, patients may be left confused and to 
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some extent unnecessarily worried once they hear the 
word ‘familial.’ It is important to properly discuss with 
patients that close monitoring is the only way forward 
at the moment. Any of their relatives who may have got 
a thyroid condition should not take it lightly and should 
consult their endocrinologist for advice.
Clinicians should keep a lower threshold for invasive 
investigations like FNAC, for such patients who may 
fulfil the criteria of FPTC. The treatment plans for such 
patients should be discussed in multidisciplinary meetings 
and possibility of FPTC should be considered in high-
risk patients. The aggressive nature of the condition may 
require more extensive surgery compared to sporadic 
forms of PTC. This has to be decided on individual basis, 
and at this stage, there is not enough evidence to suggest 
definitive treatment plan for all such patients. Familial 
nature of PTC remains a sensitive issue in clinical practice 
and due attention has to be paid to discuss it properly.
Multifocal papillary carcinoma is the most common 
biopsy finding in patients with FPTC.[7] Biopsy of two 
of three sisters reported this pattern. Population-based 
studies have confirmed increased incidence of PTC in up 
to the third-degree relatives. Oakley et al. found that first-, 
second-, and third-degree relatives of PTC patients had a 
significantly higher risk of developing FPTC compared 
with general population used as controls. The first-degree 
relatives of the patients of FPTC were at a 5.4-fold 
increased risk (P <10−15) of being diagnosed as having 
this cancer themselves. The second- and third-degree 
relatives had a 2.2-fold (P <10−11) and 1.8-fold increased 
risk (P < 10−8), respectively. Siblings of patients were at 
highest risk (odds ratio, 6.8; P < 10−15).[4] It is interesting 
to note that up to the third-degree relatives have higher 
incidences of FPTC. Involvement of up to the third-degree 
relatives makes genetic cause a very likely possibility; 
however, since the pattern of inheritance remains unclear, 
it is not possible so far to use it in clinical settings properly. 
It is important to remember that most population studies 
have recorded only numbers of patient with PTC and not 
recorded the type and nature of papillary cancer. It would 
be interesting to see if the nature aggressiveness of PTC 
could be recorded as well. Since other smaller data size 
studies have suggested, FPTC is a more aggressive form 
of disease; it would be interesting if further studies could 
differentiate PTC on the basis of aggressiveness of tumour.
This family showed some important clinical facts about 
inheritance of FPTC not reported in literature before. The 
age of diagnosis was very similar in all sisters. Two of 
them were diagnosed soon after their first presentation 
to specialist endocrinology unit following the first FNA 
while one sister was disease-free 10 years ago on FNA. 
FPTC generally presents at a younger age, but presentation 
at almost the same age is an interesting finding. All sisters 
lived in different parts of world and were exposed to 
different environmental conditions. Development of PTC 
in most of these sisters suggests a strong genetic influence 
in occurrence of FPTC. Population-based studies have also 
suggested a stronger genetic influence as the incidence 
is higher in up to the third-degree relatives; however, 
the incidence is not statistically significant in spouses of 
these patients.[4]
FPTC is usually more aggressive than its sporadic 
counterpart, but surgical treatment proved curative in all 
these patients of FPTC with no evidence of metastasis. 
This family emphasizes the strong genetic influence in 
the development of FPTC. Environmental factors may 
influence the development of FPTC, but it does not seem 
to be a strong factor in these patients. All these patients 
were diagnosed at very similar age, and it may be useful 
to screen relatives of patients with strong family history 
of FPTC at the age of diagnosis of the first patient.
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